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patients from 2000 to 2007 were matched 1:10 by age and gender to cancer-free 
controls selected from the PHARMO RLS with date of diagnosis as the index date 
for both RCC patients and their controls. TE events were deﬁned as any venous TE 
event or arterial TE event requiring hospitalization in the 12 months before or after 
index date. RESULTS: A total of 973 RCC patients were included, 6% of whom 
underwent nephrectomy. The proportion of patients with any TE event was similar 
before (2.0%, 95% CI: 1.2–3.0%) and after (1.4%, 95% CI: 0.8–2.4%) RCC diag-
nosis. Arterial TE events were more common prior to diagnosis (1.6%, 95% CI: 0.9–
2.7%) than post-diagnosis (0.5%, 95% CI: 0.2–1.2%), whereas venous TE events 
were less common prior to diagnosis (0.3%, 95% CI: 0.1–0.9%) than post-diagnosis 
(0.9%, 95% CI: 0.4–1.8%). Compared to cancer-free controls, RCC patients were 
more likely to have had a pre-diagnosis (odds ratio  2.7, 95% CI: 1.6–4.4) or post-
diagnosis (hazard ratio  2.1, 95% CI: 1.2–3.7) TE event. CONCLUSIONS: In this 
population-based study, RCC patients were twice as likely to develop TE events 
compared to cancer-free controls, although frequency of events was low. These results 
emphasize the need for careful observation of RCC patients after diagnosis.
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OBJECTIVES: TO compare efﬁcacy and safety of lenograstim and ﬁlgrastim in stem 
cell mobilization in healthy donors (allogenic transplantation) and in oncological 
patients (autologous transplantation). METHODS: Comparison was based on ran-
domized controlled trials (RCTs) identiﬁed by means of systematic review, carried out 
according to the Cochrane Collaboration guidelines. The most important medical 
databases were searched (EMBASE, MEDLINE, CENTRAL). Two reviewers indepen-
dently selected trials, assessed their quality and extracted data. Meta-analysis of 
head-to-head trials was performed to compare lenograstim and ﬁlgrastim in stem cell 
mobilization in healthy donors and oncological patients. RESULTS: The results of 4 
RCTs in healthy donors and 3 RCTs in oncological patients were included in the 
analysis. For healthy donors mobilization with lenograstim resulted in higher number 
of CD34 cells harvested than mobilization with ﬁlgrastim (WMD  0.66 r 106 per 
kg of body weight [0.05; 1.26]). No differences between lenograstim and ﬁlgrastim 
were found in the number of donors requiring second apheresis (RR  0.91 [0.62; 
1.35]). Adverse events rates were similar in both arms. Most common adverse events 
including bone pain and arthralgia. For oncological patients no differences in the 
number of patients that gained target CD34 cells (2 r 106) were found (RR  0.72 
[0.33; 1.55]). Results for hematological recovery are inconsistent. No signiﬁcant 
differences in the incidence of neutropenia were noted (RR  0.72 [0.50; 1.03]) 
whereas platelet transfusions were more frequent in ﬁlgrastim treated patients than in 
lenograstim group (RR  0.16 [0.04; 0.67]). The length of hospital stay after trans-
plantation was similar in both groups. No signiﬁcant differences regarding safety 
outcomes were reported. CONCLUSIONS: In healthy donors lenograstim is more 
potent than ﬁlgrastim in stem cell mobilization into peripheral blood and no differ-
ences in safety proﬁles between two drugs were noted. In oncological patients both 
drugs has similar impact on stem cell mobilization while lenograstim dicreases the 
risk of platelet transfusion. Acknowledgements: This analysis was supported by     
Sanoﬁ-Aventis.
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OBJECTIVES: This study compared efﬁcacy and safety of allogenic peripheral blood 
stem cell transplantation (PBSCT) after mobilization with either lenograstim or ﬁl-
grastim. METHODS: Comparison was based on randomized controlled trials (RCT) 
identiﬁed by means of systematic review, carried out according to the Cochrane Col-
laboration guidelines. The most important medical databases were searched (EMBASE, 
MEDLINE, CENTRAL). Two reviewers independently selected trials, assessed their 
quality and extracted data. Since head-to-head trials were not found, indirect com-
parison using Bucher’s method was performed. RESULTS: The results of 2 RCTs for 
PBSCT after lenograstim mobilization and 7 for PBSCT with ﬁlgrastim were included. 
In all trials PBSCT was compared with bone marrow transplantation (BMT). No sig-
niﬁcant differences between lenograstim and ﬁlgrastim were found in mortality rate 
(RR  0.84 [0.49; 1.42]) and relapse rate (RR  0.69 [0.19; 2.49]). PBSCT after 
mobilization with lenograstim comparing to BMT does not increase the risk of acute 
graft versus host disease (GvHD) (RR  1.06 [0.73; 1.53]) whereas PBSCT after ﬁl-
grastim use is associated with higher risk of acute GvHD than BMT (RR  1.19 [1.03; 
1.37]). However indirect comparison results in similar incidence of acute GvHD 
(RR  0.89 [0.60; 1.32]. The was also no difference between lenograstim and ﬁlgrastim 
in respect to chronic GvHD (RR  1.33 [0.84; 2.11]. Lenograstim and ﬁlgrastim 
in PBSCT resulted in similar mortality rate due to GvHD (RR  0.55 [0.19; 1.59]), 
treatement realted mortality (RR  1.11 [0.60; 2.04]). No differences in hospital 
admissions for donors mobilized with lenograstim and ﬁlgrastim were identiﬁed 
(RR  1.04 [0.60; 1.79]). CONCLUSIONS: Indirect comparisons indicate similar 
efﬁcacy and safety of PBSCT after mobilization with lenograstim and PBSCT after 
mobilization with ﬁlgrastim. Acknowledgements: This analysis was supported by     
Sanoﬁ-Aventis.
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OBJECTIVES: To describe the prevalence of comorbidities in the newly diagnosed 
mCRC population. METHODS: The study used a large US claims database. Patients 
aged q18 with newly diagnosed mCRC between January 2005 and June 2008 were 
selected using the ICD-9 diagnosis codes (CRC: 153.x [excluding 153.5], 154.0, 154.1, 
154.8; distant metastasis: 196.0, 196.1, 196.3, 196.5, 197.x (excluding 197.5), 198, 
199.0). The initial mCRC diagnosis date was deﬁned as the index date. One-year 
continuous medical and drug beneﬁt coverage prior to the index date was required. 
Medical diagnoses and medication treatments were examined. All comorbidities were 
estimated during 1-year except for traumatic conditions which were assessed for 30-
day prior to the index date. RESULTS: Based on the selection criteria, 12,648 patients 
were included with mean (ostandard deviation) age of 66.3 (o13.0) years, 54% male, 
and 70% with colon primary. Distribution of metastases included liver (40%), lung 
(14%), bone (6%), and brain (3%). The most prevalent comorbidity was cardiovas-
cular disease (CVD) (62% of patients) including hypertension (41%), coronary artery 
disease (17%), congestive heart failure (7%), dysrhythmias (14%), arterial thrombo-
embolism including ischemic heart disease (18.6%), and venous thromboembolism 
(6%). Over 10% of patients had a major surgery, bone fracture, or open wound 30 
days prior to mCRC diagnosis; 31% had a history of bleeding; and nearly 12% of 
patients were treated with anticoagulant and 6% with antiplatelet agents. Addition-
ally, 19% of patients had diabetes, 8% had renal failure or insufﬁciency, and 5% had 
skin disorders. Patients q65 years old had a signiﬁcantly higher CVD prevalence (73%; 
p  0.001). CONCLUSIONS: Comorbid medical conditions are common in patients 
with mCRC. CVD is the most prevalent comorbidity and affects approximately ¾ of 
patients over age 65. It is important to assess comorbidities in all patients with mCRC 
since their presence may impact treatment decision making.
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OBJECTIVES: Current options for colorectal cancer (CRC) screening include imaging 
procedures such as colonoscopy and ﬂexible sigmoidoscopy, guaiac fecal occult blood 
tests (gFOBT), and fecal immunochemical tests (FIT). Compliance with screening for 
CRC guidelines remains low among average-risk adults, at least partly because of low 
patient acceptance of available tests due to their invasiveness, inconvenience, and 
perceived safety risks. Serum tests are noninvasive, convenient, and safe, and may 
improve compliance. We systematically reviewed the literature to assess the current 
status of serum tests and other screening tests for CRC. METHODS: We analyzed 
studies of CRC screening tests identiﬁed in a search of English-language MEDLINE-
indexed articles published in the 3 years prior to March 2009 and non-MEDLINE-
indexed sources such as organization websites, meeting abstracts, and government 
publications. RESULTS: We identiﬁed 123 primary studies from MEDLINE and 45 
from non-MEDLINE sources for a total of 168 pertaining to tests or biomarkers for 
early diagnosis of CRC. Serum biomarkers being evaluated include tumor associated 
antigens, cytokines, anti-apoptotic and pro-growth factors, and hypermethylated 
DNA. Biomarkers under development have signiﬁcantly higher sensitivity for CRC 
than for adenomatous polyps, making them more effective for cancer detection than 
prevention. CRC sensitivity and speciﬁcity of certain serum biomarkers and serum 
biomarker panels under development are better than those of the existing test gFOBT 
and equivalent or better than those of FIT. However, most biomarkers in development 
are common to other cancers and diseases, reducing their speciﬁcity for CRC. CON-
CLUSIONS: Several serum biomarkers show promise in detecting CRC, but require 
testing in large, average-risk populations. Unless biomarkers are identiﬁed that are 
more speciﬁc for adenomas and/or CRC than currently known, and because of the 
heterogeneity of CRC, the approach most likely to be successful would involve the 
combination of multiple serum biomarkers to create a distinctive CRC biomarker 
proﬁle.
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OBJECTIVES: GISTs are rare tumors of the GI tract. In France, their incidence is 
estimated to be 9–12/106 inhabitants/year. Imatinib has been approved to treat 
unresectable and/or metastatic Kit-positive GISTs since 2002, but information on 
routine use, safety and efﬁcacy in unselected “real life” setting is lacking. An obser-
vational cohort (EPIGIST) in France was designed to provide data on survival, safety 
and treatment patterns and quality of life. METHODS: EPIGIST is a nationwide 
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multi-center, observational study on GIST patients treated with Imatinib between the 
availability on the French Market and the end of the 2008. Centers were randomly 
selected in national ﬁles of oncologists, gastrointestinal surgeons and specialists. The 
planned follow-up duration was three years. A case report form had to be completed 
at inclusion and during each follow-up visits. Quality of life was assessed using QLQ-
C30 and SF36 questionnaires. RESULTS: Thirty on 51 selected centers enrolled at 
least one patient and 139 patients were included (as of June 2009). The median age 
of disease onset was 58 years (range 21–86). 42% were metastatic at diagnosis. 
Primary tumors were most often stomach (48%), or bowel (34%). At diagnosis 86% 
of patients had a tumor size over 5 cm. 68% of patients had surgery of the primary 
tumor before starting Imatinib. 68% of patients were considered as high risk of relapse 
according the Miettinen classiﬁcation. For 99% of the patients, Imatinib was given at 
an initial dosage of 400 mg, 1% at 300 mg. Compliance was superior to 90% for 
99% of patients. With a median follow-up of 2.1 years, two-years overall survival 
from ﬁrst treatment with Imatinib was 83.9% (CI95%: [74.5%–90.1%]). CONCLU-
SIONS: EPIGIST is still an ongoing survey. Current results conﬁrm previous published 
data on survival in GIST treated with Imatinib in an unselected cohort of patients 
outside of a clinical trial.
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OBJECTIVES: The purpose of the study was to evaluate the relative efﬁcacy of dif-
ferent medication interventions in the treatment of metastatic renal cell carcinoma 
(mRCC) using a Bayesian mixed treatment comparison (MTC) model. METHODS: 
A systemic review was undertaken to identify randomized controlled trials assessing 
the efﬁcacy of bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus as 
stand alone therapy or in combination with interferon Alfa. The search was conducted 
within seven electronic data bases (CinAhl, AMED, Cochrane Library, Embase, 
Medline, ASCO, and Clinical trials.gov) for English language publications from incep-
tion to June 6th 2009. The Progression Free Survival (PFS) was outcome of interest in 
this study. Bayesian MTC was performed for evidence synthesis using both ﬁxed and 
random effect models. With MTC, the relative treatment effect of one intervention 
compared with another can be obtained in the absence of head-to-head evidence. 
RESULTS: Sunitinib yielded an effect size of 0.75 (95% credible interval: 0.61–0.93) 
compared to bevacizumabinterferon; 0.43 (0.31–0.75) compared to bevacizumab; 
0.54 (0.37–0.85) compared to sorafenib; 0.74 (0.57–0.96) compared to temsirolimus; 
and 0.97 (0.57–1.57) compared to everolimus. CONCLUSIONS: The relative efﬁcacy 
of sunitinib was better than all medication interventions on PFS except everolimus in 
the treatment of mRCC.
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OBJECTIVES: In the Netherlands, additional funding of expensive hospital drugs 
requires an assessment of real-world cost-effectiveness within 3 years after implement-
ing. We explored the use and limitations of real-world data for the economic evalua-
tion of oxaliplatin plus standard adjuvant treatment in stage III colon cancer.            
METHODS: Real-world data were gathered from the Dutch population-based Cancer 
Registry supplemented with data from medical records. Patients additionally treated 
with oxaliplatin (N  101) were compared to patients receiving only standard adjuvant         
therapy (N  105). Moreover, comparisons were made between our ﬁndings and         
results from the randomised controlled trial (RCT) that demonstrated a signiﬁcantly 
improved disease-free survival with oxaliplatin, on which current Dutch treatment   
guidelines are based. RESULTS: Patients receiving oxaliplatin are signiﬁcantly younger 
and have fewer comorbidities than patients receiving alternative chemotherapy. 
Median follow-up time of the study was 26.6 months. The adjusted hazard ratio for   
disease-free survival of 0.84 indicated that oxaliplatin was more effective. However, 
the 95% conﬁdence interval of 0.35–2.03 revealed large uncertainty about the actual 
effectiveness in daily clinical practice. Moreover, residual confounding could not be 
ruled out. On the other hand, patient characteristics, treatment patterns, comparator 
arm, dosages, toxicities, resource use, costs and disease-free survival outcomes 
obtained in clinical daily practice showed great similarities with the RCT based data 
and results. During our study, extended 6-year RCT follow-up results became avail-
able which conﬁrmed previous ﬁndings. CONCLUSIONS: Insight into patient char-
acteristics, treatment patterns, dosage and toxicities observed in daily clinical practice 
is very useful in determining the extent to which RCT results are generalisable to a 
real-world setting. However, outcomes research alone does not necessarily lead to 
internally valid and precise estimates of effectiveness and cost-effectiveness. In these 
situations, assessment of real-world cost-effectiveness should be based on a careful 
synthesis of RCT results and real-world observations.
PCN13
A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE 
BEVACIZUMAB  INTERFERON ALPHA-2A VS SUNITINIB IN 
METASTATIC RENAL CELL CARCINOMA
Mickisch GH1, Schwander B2, Escudier B3, Bellmunt J4, Maroto P5, Porta C6, Walzer S7, 
Siebert U8
1Center of Operative Urology Bremen, Bremen, Germany, 2AiM GmbH Assessment in 
Medicine, Schopfheim, Germany, 3Institut Gustave Roussy, Villejuif, France, 4University 
Hospital del Mar. UPF, Barcelona, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, 
Spain, 6IRCCS San Matteo University Hospital Foundation, Pavia, Italy, 7F. Hoffmann-La 
Roche Pharmaceuticals AG, Basel, Switzerland, 8UMIT—University for Health Sciences, 
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OBJECTIVES: Bevacizumab (BEV)  Interferon-alpha-2a (IFN-A) and sunitinib (SUN) 
have shown signiﬁcant increase in progression free survival (PFS) compared to IFN-A 
in ﬁrst-line metastatic renal cell carcinoma (mRCC) therapy. There is no head-to-head 
evidence available comparing both regimens, however there is an increasing need to 
assess and compare the relative efﬁcacy and effectiveness of both therapy approaches.          
METHODS: We applied the widely accepted indirect comparison method (Bucher 
et al. J Clin Epidemiol 1997) to PFS data of the pivotal phase III trials, that is, the 
unadjusted investigator-assessed PFS hazard ratios (HR) for BEV      IFN-A vs. IFN-A 
(0.63) and for SUN vs IFN-A (0.52). To enable valid indirect comparison, the IFN-A 
control arms of both trials have been standardised by recalculating the indirect HR 
and transferring them into direct HR estimates using the cross-trial proportions. In          
addition, we adjusted for effects of down-dosing and patient compliance based on 
published evidence. Sensitivity analyses on adjustment components have been per-
formed. RESULTS: The unadjusted indirect efﬁcacy comparison resulted in a statisti-      
cally non-signiﬁcant PFS difference of SUN vs BEVIFN-A (HR: 0.82; 95% CI: 
0.64–1.06; p  0.13). Standardising the IFN arms and simulating realistic scenarios         
for SUN down-dosing and patient compliance results in similar PFS HRs for BEV       IFN-
A (HR: 0.63) and Sunitinib (HR: 0.64) as compared to IFN alone. The adjusted indi-   
rect PFS HR of SUN vs BEV  IFN-A was 1.025 (95% CI: 0.81–1.30; p  0.83). 
Results were mostly inﬂuenced by IFN-A control arm adjustment, followed by patient 
compliance and down-dosing. CONCLUSIONS: Based on our comparative effective-
ness evaluation in ﬁrst-line mRCC therapy, there is no statistically signiﬁcant evidence 
for a difference in efﬁcacy and effectiveness regarding PFS between    BEVIFN-A and 
SUN. These ﬁndings imply that additional treatment decision criteria such as tolerabil-
ity need to be considered to guide treatment decisions.
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OBJECTIVES: New treatment options are needed for advanced NSCLC offering 
improved progression-free (PFS) and overall survival (OS) over standard chemother-
apy. Bevacizumab, a humanised monoclonal antibody (MAb) against VEGF, plus 
chemotherapy increases PFS and OS in advanced NSCLC patients versus chemother-
apy alone4–5. Cetuximab, a MAb targeting EGFR, showed signiﬁcant OS when com-
bined with chemotherapy3. This study compared the clinical beneﬁts for NSCLC 
patients treated with BCG or BCP to CVC using indirect treatment comparison (ITC) 
methodology. METHODS: In the absence of head-to-head trials, ITC1–2 was per-
formed on patients with non-squamous NSCLC comparing the relative beneﬁt of 
ﬁrst-line therapies BCG/BCP versus CVC by hazard ratios (HR) adjusted for differ-
ences in underlying chemotherapy and populations. Where HRs were not reported, 
HRs1 and standard errors6 were estimated. Based on the ITC a statistical disease model 
was developed to estimate the adjusted time in PFS and OS. RESULTS: ITC-estimated 
HRs for the primary endpoints in AVAiL4 and E45995 showed that the adjusted PFS 
HR for BCG versus CVC was 0.80 resulting in an expected time spent in PFS for BCG 
of 9.62 versus 7.99 months for CVC. Model-derived data showed BCP treatment in 
patients with adenocarcinoma histology resulted in adjusted BCP HR of 0.89 versus 
CVC. Model data also showed that BCP patients experienced on average, 19.55 
versus. 17.57 months (CVC) of OS. Sensitivity analyses conﬁrmed the robustness of 
these ﬁndings. CONCLUSIONS: Interpretation of ITC ﬁndings are limited due to 
cross-study heterogeneity. However results show that BCG or BCP therapy in patients 
with advanced non-squamous NSCLC brings a superior beneﬁt in terms of OS and 
PFS compared with CVC therapy.
